Investigating genetic and microbial factors that affect the severity of Atopic Dermatitis.
Official title: Genetic and microbial modifiers of Atopic Dermatitis (AD): Mechanisms of increased AD severity in patients with the R576 polymorphism in IL-4Ra and impact of S aureus skin decolonization on AD
Funded at Boston Children's Hospital · NIH-11066508 · Data updated 2026-11-12
This study is looking at how certain genes and skin bacteria might affect how bad Atopic Dermatitis (AD) can get, and it's for people of all ages who have this condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2020 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $510,170 |
| NIH project number | 5U01AI152033-06 |
| Project ID | NIH-11066508 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Atopic Dermatitis, particularly those with the R576 polymorphism in IL-4Ra.
✕Less likely to help
Patients without Atopic Dermatitis or those not carrying the specific genetic marker may not benefit from this research.
What this research studies
This research explores how specific genetic variations and the presence of certain bacteria on the skin can influence the severity of Atopic Dermatitis (AD). The team of experienced researchers will analyze patients with a particular genetic marker (R576 polymorphism in IL-4Ra) and assess the effects of decolonizing Staphylococcus aureus bacteria from the skin. By recruiting participants from various clinics, they aim to gather comprehensive data on both pediatric and adult populations. The study employs advanced clinical and laboratory techniques to better understand the mechanisms behind AD and improve treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from Atopic Dermatitis by targeting genetic and microbial factors.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetics and microbial factors in allergic diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Geha, Raif Salim — Boston Children's Hospital
- Study coordinator: Geha, Raif Salim
Related research
Other NIH-funded projects on the same topics.
-
How genes and skin bacteria affect eczema severity
This project looks at whether a common gene change and Staphylococcus aureus on the skin make eczema worse in children and adults and whether removing the bacteria helps.
-
Stopping Atopic Dermatitis and Allergy: Preventing Food Allergy by Protecting the Skin
A large study in infants at high risk for allergies tests whether using a skin barrier cream together with early, proactive skin care can prevent peanut allergy and other food allergies.
-
SEAL Study: Preventing peanut allergy by protecting baby skin
This trial tests whether using a skin-emollient and proactive skin steroids early in life can prevent peanut allergy in high-risk infants.
-
SEAL Study: Prevent allergy by protecting the baby’s skin
A very young group of high-risk babies will try a early skin-care plan to reduce eczema and prevent peanut allergy.
-
Understanding how skin fungi affect atopic dermatitis in adults
A study will look at how the skin's fungal community influences atopic dermatitis in adults and whether this understanding could lead to new treatments.
-
Preventing eczema-related allergies by strengthening infants' skin barrier
This project will see if using a trilipid skin cream plus proactive mild topical steroids in infants with early dry skin or eczema lowers their chances of developing food allergies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.